LEXX Message Board Post 9638608 | Lexaria Bioscience Corp.
home / stock / lexx / lexx message board
Ultimate
(investorshub)
Posted on: Apr/19/2023 04:10:54
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171719782
VOTE NO on repricing options. Management has consistently
News, Short Squeeze, Breakout and More Instantly...
-
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
-
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
-
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...